Yisheng Biotechnology Co is a biopharmaceutical company specializing in the research and production of pluripotent stem cell differentiation cell drugs, focusing on the development and industrialization of pancreatic islet therapies and the construction of a universal platform.

The core team is composed of young innovative talents from top international universities such as Peking University, Tsinghua University, and the University of Cambridge.

The company has established a research and production center in Beijing and a wholly-owned research laboratory in Cambridge, UK (ACESO BIOSCIENCES). The Cambridge laboratory was selected for the "2023 Zhongguancun National Independent Innovation Demonstration Zone Project to Enhance International Development Level".

In March 2022, Yisheng Biotech landed in the Daxing part of the Beijing Daxing International Airport Economic Zone and was selected as a leading enterprise founded by talents in the "New National Gate" Project of Daxing district in the same year.

Its production base within the park is expected to start operation in July 2024. The production capacity will be mainly used for the preclinical research of the company's first independently developed drug, ESN5800 (pluripotent stem cell differentiated islet cell therapy for type 1 diabetes), and for conducting phase 1 clinical trials in China and the UK.